HUP0401620A2 - Orális antidiabetikus hatóanyagok és eljárás előállításukra - Google Patents
Orális antidiabetikus hatóanyagok és eljárás előállításukraInfo
- Publication number
- HUP0401620A2 HUP0401620A2 HU0401620A HUP0401620A HUP0401620A2 HU P0401620 A2 HUP0401620 A2 HU P0401620A2 HU 0401620 A HU0401620 A HU 0401620A HU P0401620 A HUP0401620 A HU P0401620A HU P0401620 A2 HUP0401620 A2 HU P0401620A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- substituted
- heteroaryl
- hydrogen atom
- aryl
- Prior art date
Links
- 239000003538 oral antidiabetic agent Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- -1 2-phenyl-5-methyl-oxazol-4-yl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
A találmány szerinti vegyületek (I) általános képletében A jelentésearilcsoport, szubsztituált arilcsoport, heteroarilcsoport,szubsztituált heteroarilcsoport, fuzionált heteroarilcsoport,szubsztituált fuzionált heteroarilcsoport, cikloalkilcsoport,szubsztituált cikloalkilcsoport, heterocikloalkilcsoport vagyszubsztituált heterocikloalkilcsoport, X jelentése 2-5-atomostérköztartó csoport, amely lehet (X-1), (X-2), (X-3), (X-4) vagy (X-5)képletű csoport, ahol a hullámos vonal a kapcsolódási pontot jelzi, Qjelentése arilcsoport, szubsztituált arilcsoport, heteroarilcsoport,szubsztituált heteroarilcsoport, fuzionált heteroarilcsoport vagyszubsztituált fuzionált heteroarilcsoport, azzal a megszorítással,hogy ha Q jelentése 5 tagú heteroarilcsoport, akkor az X csoport a Qcsoporthoz a heteroarilcsoport heteroatomjától eltérő atomon keresztülkapcsolódik, Y és Z jelentése egymástót függetlenül közvetlen kötésvagy (CR1R2)n és (CR3R4)m képletű csoport, ahol R1-R4 jelentéseegymástól függetlenül hidrogénatom, halogénatom, alkilcsoport,hidroxilcsoport vagy alkoxicsoport, n és m értéke egymástólfüggetlenül 1, 2 vagy 3, B jelentése hidrogénatom, halogénatom,alkilcsoport, halogénalkilcsoport vagy alkoxicsoport, D jelentésehidrogénatom, -NH-aril vagy -NH-(szubsztituált aril) képletű csoport,alkanoilcsoport, szubsztituált alkanoilcsoport, benzoilcsoport,szubsztituált benzoilcsoport, arilcsoport, szubsztituált arilcsoport,heteroarilcsoport, szubsztituált heteroarilcsoport, cikloalkilcsoport,szubsztituált cikloalkilcsoport, heterocikloalkilcsoport vagyszubsztituált heterocikloalkilcsoport, E jelentése COR5 képletűcsoport, ahol R5 jelentése alkilcsoport, hidroxilcsoport,alkoxicsoport vagy NR6R7 képletű csoport, ahol R6 és R7 jelentéseegymástól függetlenül hidrogénatom vagy alkilcsoport, vagy R6 és R7közül az egyik jelentése hidrogénatom vagy alkilcsoport, és a másikjelentése SO2R4 képletű csoport, ahol R8 jelentése hidrogénatom vagyalkilcsoport, vagy E jelentése szubsztituált heteroarilcsoport vagy(E-1), (E-2) vagy (E-3) képletű csoport, azzal a megszorítással, hogyha A jelentése 2-fenil-5-metil-oxazol-4-il-csoport, X jelentése (X-2)képletű csoport, Q jelentése fenilcsoport, Y és Z jelentése CH2csoport, B jelentése hidrogénatom és E jelentése CO2H csoport, akkor Djelentése pirrolilcsoporttól eltérő. A találmány kiterjed a fentivegyületeket tartalmazó gyógyszerkészítményekre és a vegyületekelőállítására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31572801P | 2001-08-29 | 2001-08-29 | |
PCT/IB2002/002843 WO2003018553A1 (en) | 2001-08-29 | 2002-07-15 | Oral antidiabetic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0401620A2 true HUP0401620A2 (hu) | 2004-11-29 |
Family
ID=23225787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401620A HUP0401620A2 (hu) | 2001-08-29 | 2002-07-15 | Orális antidiabetikus hatóanyagok és eljárás előállításukra |
Country Status (35)
Country | Link |
---|---|
EP (2) | EP1577305A1 (hu) |
JP (1) | JP2005504778A (hu) |
KR (1) | KR20040044515A (hu) |
CN (1) | CN1558897A (hu) |
AP (1) | AP2002002616A0 (hu) |
AR (1) | AR036301A1 (hu) |
AT (1) | ATE323674T1 (hu) |
BG (1) | BG108597A (hu) |
BR (1) | BR0212069A (hu) |
CA (1) | CA2458621A1 (hu) |
CZ (1) | CZ2004272A3 (hu) |
DE (1) | DE60210784T2 (hu) |
EA (1) | EA200400140A1 (hu) |
EC (1) | ECSP044999A (hu) |
EE (1) | EE200400075A (hu) |
ES (1) | ES2260456T3 (hu) |
GT (1) | GT200200175A (hu) |
HN (1) | HN2002000242A (hu) |
HR (1) | HRP20040164A2 (hu) |
HU (1) | HUP0401620A2 (hu) |
IL (1) | IL159886A0 (hu) |
IS (1) | IS7114A (hu) |
MA (1) | MA27135A1 (hu) |
MX (1) | MXPA04001968A (hu) |
NO (1) | NO20040881L (hu) |
OA (1) | OA12653A (hu) |
PA (1) | PA8553701A1 (hu) |
PE (1) | PE20030563A1 (hu) |
PL (1) | PL369569A1 (hu) |
SK (1) | SK1182004A3 (hu) |
SV (1) | SV2003001213A (hu) |
TN (1) | TNSN04038A1 (hu) |
UY (1) | UY27424A1 (hu) |
WO (1) | WO2003018553A1 (hu) |
ZA (1) | ZA200400374B (hu) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059907A1 (fr) * | 2002-01-17 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Composes heterocycliques azotes : procede de preparation et d'utilisation |
PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
JP4828414B2 (ja) * | 2003-04-28 | 2011-11-30 | ニツポネツクス・インコーポレーテツド | インドール酢酸誘導体および薬剤としてのそれらの使用 |
EP1641788A1 (en) * | 2003-06-27 | 2006-04-05 | Warner-Lambert Company LLC | Preparation of n2-alkylated 1,2,3-triazoles |
JP4627298B2 (ja) * | 2003-07-02 | 2011-02-09 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾール環で置換されたインドリル誘導体およびppar調整剤としてのその使用 |
DK1648867T3 (da) * | 2003-07-17 | 2013-12-16 | Plexxikon Inc | Ppar-aktive forbindelser |
RU2367659C2 (ru) * | 2003-11-05 | 2009-09-20 | Ф.Хоффманн-Ля Рош Аг | Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) |
EP1689389A4 (en) | 2003-12-04 | 2009-06-17 | Nat Health Research Institutes | Indole compounds |
FR2863610B1 (fr) * | 2003-12-11 | 2006-01-20 | Galderma Res & Dev | NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES |
ATE359284T1 (de) * | 2003-12-11 | 2007-05-15 | Galderma Res & Dev | Neue verbindungen, bei denen es sich um modulatoren von rezeptoren vom ppar-typ handelt, und deren verwendung in kosmetischen oder pharmazeutischen zusammensetzungen |
BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
ES2314630T3 (es) * | 2004-03-09 | 2009-03-16 | F. Hoffmann-La Roche Ag | Derivados de pirazolil-indolilo en calidad de actividades. |
US7405236B2 (en) * | 2004-08-16 | 2008-07-29 | Hoffman-La Roche Inc. | Indole derivatives comprising an acetylene group |
TW200724138A (en) * | 2005-03-29 | 2007-07-01 | Sk Corp | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use |
AU2013202514B2 (en) * | 2006-04-18 | 2015-09-17 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
UY30288A1 (es) * | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
RU2435764C2 (ru) | 2006-04-18 | 2011-12-10 | Ниппон Кемифар Ко., Лтд. | АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ |
NZ588612A (en) | 2008-04-15 | 2012-08-31 | Nippon Chemiphar Co | Benzothiophen derivatives as activators of peroxisome proliferator activated receptor (PPAR) |
FR2976943B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
FR2976942B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
WO2013139341A1 (en) * | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
WO2013185766A1 (en) * | 2012-06-15 | 2013-12-19 | Syddansk Universitet | Gpr120 receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100620337B1 (ko) * | 1998-03-10 | 2006-09-13 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 |
CN1208326C (zh) * | 1998-04-23 | 2005-06-29 | 雷迪实验室有限公司 | 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物 |
JP2002527507A (ja) * | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物類、それらの調製及び使用 |
US6274608B1 (en) * | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
EP1175412A1 (en) * | 1999-04-28 | 2002-01-30 | Dr. Reddy's Research Foundation | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
WO2001017994A1 (en) * | 1999-09-08 | 2001-03-15 | Glaxo Group Limited | Oxazole ppar antagonists |
-
2002
- 2002-07-15 EP EP05104581A patent/EP1577305A1/en not_active Withdrawn
- 2002-07-15 WO PCT/IB2002/002843 patent/WO2003018553A1/en active IP Right Grant
- 2002-07-15 ES ES02745739T patent/ES2260456T3/es not_active Expired - Lifetime
- 2002-07-15 BR BR0212069-0A patent/BR0212069A/pt not_active Withdrawn
- 2002-07-15 DE DE60210784T patent/DE60210784T2/de not_active Expired - Fee Related
- 2002-07-15 AT AT02745739T patent/ATE323674T1/de not_active IP Right Cessation
- 2002-07-15 EP EP02745739A patent/EP1423363B1/en not_active Expired - Lifetime
- 2002-07-15 EE EEP200400075A patent/EE200400075A/xx unknown
- 2002-07-15 IL IL15988602A patent/IL159886A0/xx unknown
- 2002-07-15 HU HU0401620A patent/HUP0401620A2/hu unknown
- 2002-07-15 OA OA1200400053A patent/OA12653A/en unknown
- 2002-07-15 CA CA002458621A patent/CA2458621A1/en not_active Abandoned
- 2002-07-15 SK SK118-2004A patent/SK1182004A3/sk not_active Application Discontinuation
- 2002-07-15 KR KR10-2004-7003019A patent/KR20040044515A/ko not_active Application Discontinuation
- 2002-07-15 EA EA200400140A patent/EA200400140A1/ru unknown
- 2002-07-15 JP JP2003523217A patent/JP2005504778A/ja not_active Withdrawn
- 2002-07-15 CZ CZ2004272A patent/CZ2004272A3/cs unknown
- 2002-07-15 MX MXPA04001968A patent/MXPA04001968A/es unknown
- 2002-07-15 PL PL02369569A patent/PL369569A1/xx not_active Application Discontinuation
- 2002-07-15 CN CNA028216350A patent/CN1558897A/zh active Pending
- 2002-08-27 UY UY27424A patent/UY27424A1/es not_active Application Discontinuation
- 2002-08-27 PE PE2002000822A patent/PE20030563A1/es not_active Application Discontinuation
- 2002-08-27 HN HN2002000242A patent/HN2002000242A/es unknown
- 2002-08-27 PA PA20028553701A patent/PA8553701A1/es unknown
- 2002-08-27 AR ARP020103209A patent/AR036301A1/es unknown
- 2002-08-28 SV SV2002001213A patent/SV2003001213A/es not_active Application Discontinuation
- 2002-08-28 GT GT200200175A patent/GT200200175A/es unknown
- 2002-08-29 AP APAP/P/2002/002616A patent/AP2002002616A0/en unknown
-
2004
- 2004-01-15 IS IS7114A patent/IS7114A/is unknown
- 2004-01-16 ZA ZA2004/00374A patent/ZA200400374B/en unknown
- 2004-02-19 HR HR20040164A patent/HRP20040164A2/hr not_active Application Discontinuation
- 2004-02-19 MA MA27537A patent/MA27135A1/fr unknown
- 2004-02-24 BG BG108597A patent/BG108597A/bg unknown
- 2004-02-25 TN TNP2004000038A patent/TNSN04038A1/fr unknown
- 2004-02-27 NO NO20040881A patent/NO20040881L/no not_active Application Discontinuation
- 2004-03-03 EC EC2004004999A patent/ECSP044999A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401620A2 (hu) | Orális antidiabetikus hatóanyagok és eljárás előállításukra | |
CY1106858T1 (el) | Νεα παραγωγα κυκλικου αμιδιου | |
HUP0402309A2 (hu) | Glükokináz-aktivátorként szolgáló amidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
CY1108313T1 (el) | Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6 | |
HUP0400323A2 (hu) | Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0001140A2 (hu) | Szubsztituált pirimidinon és piridonszármazékok, továbbá ezeket tartalmazó gyógyászati készítmények | |
CY1118805T1 (el) | Νεες μορφες 5-αζακιτιδινης | |
HUP0000434A2 (hu) | 1,4-Szubsztituált gyűrűs aminszármazékok | |
DE69323630T2 (de) | Benzokondensierte verbindungen | |
CY1106237T1 (el) | Ετepοκυκλικα παραγωγα με 5 μελη στο δακτυλιο και εφαρμογη αυτων ως παρεμποδιστων της μονοαμινο οξυδασης | |
HUP0001848A2 (hu) | NOS gátló 6-fenil-piridil-2-amin származékok | |
HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
DK0652868T3 (da) | Hæmmere af c-AMP-phosphodiesterase | |
DK0682033T3 (da) | Hydrolyserbare og polymeriserbare silaner | |
HUP0300080A2 (hu) | Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401886A2 (hu) | Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402019A2 (hu) | CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0105108A2 (hu) | Amidvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0002853A2 (hu) | 6,7-Helyzetben aszimmetrikusan diszubsztituált kinoxalinkarbonsav-származékok, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
NO165921C (no) | Fremgangsmaate for fremstilling av disubstituerte prolinderivater. | |
CY1108148T1 (el) | Αβερμεκτινης- και μονοσακχαριτη αβερμεκτινης παραγωγα υποκατεστημενα στην 4''- ή 4'- θεση που εχουν ζιζανιοκτονες ιδιοτητες | |
HUP0004588A2 (hu) | Szubsztituált 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-ol-származékok, eljárás előállításukra és alkalmazásuk gyógyszerként, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0000321A2 (hu) | NOS inhibitor hatású aromás aminszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
DE69314911T2 (de) | Cis-epoxide Derivate, verwendbar als irreversible HIV-Protease Inhibitoren und Verfahren und Zwischenprodukte zu ihrer Herstellung | |
HUP9902199A1 (hu) | Új nitronszármazékok, ezek előállítási eljárása és ezeket tartalmazó gyógyszerkészítmények |